Digital product passports as enablers of digital circular economy: a framework based on technological perspective

Taking into consideration the existing Industry 4.0 infrastructures and the rise of Industry 5.0 (I5.0), more and more solutions are being developed, aiming towards increased environmental consciousness through advanced technologies, and human centricity. However, there are ongoing requirements on data traceability, and access to the related actors, to ensure the establishment of sustainable solutions, within the context of a digital circular economy (DCE) environment. Digital product passports (DPPs) constitute such novel technological solution that can enable the transition toward DCE and sustainable I4.0 and I5.0, as digital identities that are assigned to physical products, capable of tracing their lifecycles through data such as their technical specifications, usage instructions, and repair and maintenance information. Although the respective research community has started providing a thorough analysis of DPPs potential to constitute a CE enabler, their technical requirements are still unclear. As part of our contribution to this issue, we propose a fundamental CE framework with integrated DPP characteristics, with the potential of being adapted in different sector stages for the generation and distribution of DPPs both for stakeholders and consumers. The corresponding solution is further supported through a systematic literature review that follows a technological approach to the DPPs implementation

Mutant KRAS promotes malignant pleural effusion formation

Malignant pleural effusion (MPE) is the lethal consequence of various human cancers metastatic to the pleural cavity. However, the mechanisms responsible for the development of MPE are still obscure. Here we show that mutant KRAS is important for MPE induction in mice. Pleural disseminated, mutant KRAS bearing tumour cells upregulate and systemically release chemokine ligand 2 (CCL2) into the bloodstream to mobilize myeloid cells from the host bone marrow to the pleural space via the spleen. These cells promote MPE formation, as indicated by splenectomy and splenocyte restoration experiments. In addition, KRAS mutations are frequently detected in human MPE and cell lines isolated thereof, but are often lost during automated analyses, as indicated by manual versus automated examination of Sanger sequencing traces. Finally, the novel KRAS inhibitor deltarasin and a monoclonal antibody directed against CCL2 are equally effective against an experimental mouse model of MPE, a result that holds promise for future efficient therapies against the human condition

Towards a Hybrid Multi-Layer Blockchain-Based Energy Trading Market for Microgrids

Energy trading is currently transitioning from traditional centralized markets to decentralized peer to peer (P2P) solutions. More and more P2P projects are operating with the Blockchain technology, hosting e-auctions for prosumers who are part of microgrids and operating in the same network. This way of energy trading might be ideal for trading types of renewable energy with high predictability but the same does not apply for lower predictability types, such as solar energy. A critical issue of P2P energy trading markets, that operate only in the context of local energy communities, is the availability of resources when every prosumer adapts the same role in the market, thus leading to either large excess or deficit of energy. This paper introduces a blockchain-based semi-decentralized (hybrid) energy trading market that consists of more than one microgrids and each microgrid is composed of prosumers who produce and trade energy with others within their microgrid. Furthermore, inter-microgrid energy trading can be initiated, as well as trading with the main grid, when there are unmet energy requests. In order to ensure safety and security between untrusted parties, transactions happen in a permissioned blockchain network. As an alternative way to trade energy this solution proposes along with the Fungible Tokens, the use of Non-Fungible Tokens (NFT) that enclose amounts of energy to be used when needed. Each microgrid is equipped with an appropriately sized battery, a repository to maintain profits, and is coordinated by an administration manager, who is responsible for transactions happening outside of the microgrid

Pleural Mesothelioma in a young male patient

We present the case of a 33-year-old male patient suffering from lymphocytic pleural effusion, as a result of pleural mesothelioma. Mesothelioma is a malignant tumor of the pleura that is mainly caused by chronic exposure to asbestos fibers and more than 40 years of exposure are needed to develop the disease. Early studies on the relationship of asbestos and mesothelioma were issued in the 1960s. Fibers migrate from the parenchyma of the lung to the visceral pleura. It is widely known that asbestos is an oncogenic factor which can cause damage to DNA. A chest x-ray may reveal pleural effusion with or without pleural thickening, whereas a chest CT may also reveal pleural thickening, uniform and/or lobular. Specific tests, such as immunohistochemical staining, are used in order to help differential diagnosis. Extrapleural pneumonectomy is used as a therapeutic option which involves removal of the lung as well as both the visceral and parietal pleura, the affected part of the pericardium and diaphragm. Surgery should be followed up by radiotherapy and chemotherapy. The surgery may lead to a mean survival rate of approximately 9-21 months. The case presented underlines that in the event of pleural effusion with a lymphocyte type physicians should consider the possibility of a pleural mesothelioma during differential diagnosis, even in relatively young patients

ELECTRON: An Architectural Framework for Securing the Smart Electrical Grid with Federated Detection, Dynamic Risk Assessment and Self-Healing

The electrical grid has significantly evolved over the years, thus creating a smart paradigm, which is well known as the smart electrical grid. However, this evolution creates critical cybersecurity risks due to the vulnerable nature of the industrial systems and the involvement of new technologies. Therefore, in this paper, the ELECTRON architecture is presented as an integrated platform to detect, mitigate and prevent potential cyberthreats timely. ELECTRON combines both cybersecurity and energy defence mechanisms in a collaborative way. The key aspects of ELECTRON are (a) dynamic risk assessment, (b) asset certification, (c) federated intrusion detection and correlation, (d) Software Defined Networking (SDN) mitigation, (e) proactive islanding and (f) cybersecurity training and certification

Mutant <em>KRAS </em>promotes malignant pleural effusion formation.

Malignant pleural effusion (MPE) is the lethal consequence of various human cancers metastatic to the pleural cavity. However, the mechanisms responsible for the development of MPE are still obscure. Here we show that mutant KRAS is important for MPE induction in mice. Pleural disseminated, mutant KRAS bearing tumour cells upregulate and systemically release chemokine ligand 2 (CCL2) into the bloodstream to mobilize myeloid cells from the host bone marrow to the pleural space via the spleen. These cells promote MPE formation, as indicated by splenectomy and splenocyte restoration experiments. In addition, KRAS mutations are frequently detected in human MPE and cell lines isolated thereof, but are often lost during automated analyses, as indicated by manual versus automated examination of Sanger sequencing traces. Finally, the novel KRAS inhibitor deltarasin and a monoclonal antibody directed against CCL2 are equally effective against an experimental mouse model of MPE, a result that holds promise for future efficient therapies against the human condition

Mutant KRAS promotes malignant pleural effusion formation

Malignant pleural effusion (MPE) is the lethal consequence of various human cancers metastatic to the pleural cavity. However, the mechanisms responsible for the development of MPE are still obscure. Here we show that mutant KRAS is important for MPE induction in mice. Pleural disseminated, mutant KRAS bearing tumour cells upregulate and systemically release chemokine ligand 2 (CCL2) into the bloodstream to mobilize myeloid cells from the host bone marrow to the pleural space via the spleen. These cells promote MPE formation, as indicated by splenectomy and splenocyte restoration experiments. In addition, KRAS mutations are frequently detected in human MPE and cell lines isolated thereof, but are often lost during automated analyses, as indicated by manual versus automated examination of Sanger sequencing traces. Finally, the novel KRAS inhibitor deltarasin and a monoclonal antibody directed against CCL2 are equally effective against an experimental mouse model of MPE, a result that holds promise for future efficient therapies against the human condition